Celista Duo lozenges 40 pieces

• active ingredients: dequalinium chloride, cinchocaine hydrochloride;
• 1 tablet contains: dequalinium chloride 0.25 mg, cinchocaine hydrochloride (dibucaine hydrochloride) 0.03 mg;
• Excipients: sorbitol (E 420), talc, colloidal anhydrous silicon dioxide, magnesium stearate, mint flavoring, peppermint oil.

Hypersensitivity to dequalinium chloride, cinchocaine hydrochloride (dibucaine hydrochloride), other quaternary ammonium compounds (e.g. benzalkonium chloride), or any of the excipients of the drug.

Sometimes hypersensitivity reactions may occur after using the drug, such as rash, itching, burning sensation, irritation of the mucous membrane of the mouth and throat. In rare cases, namely in case of abuse, ulceration and necrosis may occur. In case of any unusual reactions, the drug should be discontinued and a doctor should be consulted regarding further therapy.

Adults and children over 12 years of age – prescribe 1 tablet every 2 hours, after the symptoms of inflammation have subsided – 1 tablet every 4 hours.

Children over 4 years old – prescribe 1 tablet every 3 hours, after the symptoms of inflammation have subsided – 1 tablet every 4 hours.

The maximum daily dose is 10-12 tablets during the acute phase and 6 tablets after the inflammatory symptoms disappear.

The tablets should be slowly dissolved without chewing. The duration of treatment is determined by the doctor individually. The patient should consult a doctor if the symptoms have not disappeared or worsened after 5 days of using the drug.

Since the medicine does not contain sugar, it is suitable for use by diabetics.

The medicine contains sorbitol, so it should not be used in patients with rare hereditary diseases such as fructose intolerance syndrome.

Use with caution in patients with low plasma cholinesterase levels.

Use during pregnancy or breastfeeding

Pregnancy. Controlled studies have not been conducted. The drug can be used during pregnancy after consultation with a doctor if the expected therapeutic effect outweighs the possible risk to the fetus.

Breastfeeding. Clinical studies on the penetration of active substances into breast milk have not been conducted, therefore the drug is not recommended for use during breastfeeding.

Children

The drug in this dosage form should not be prescribed to children under 4 years of age.

Ability to influence reaction speed when driving vehicles or other mechanisms

Studies on the effect of the drug on the ability to drive and use other mechanisms have not been conducted. However, the likelihood of such an effect is very low.

The drug is generally well tolerated. In case of overdose, nausea, vomiting, and in rare cases, ulcers and necrosis of the esophagus are possible.

Treatment of overdose is symptomatic; if necessary, enveloping agents can be used.

Do not induce vomiting or perform gastric lavage.

The antibacterial activity of dequalinium is reduced when used simultaneously with anionic surfactants, which may be part of toothpaste.

The use of the drug should not be combined with the use of cholinesterase inhibitors.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.